Radiation Oncology/Trial acronyms
Listing of Oncology Clinical Trial Acronyms
This listing is for names of trials with acronyms. It should not be used to include trial results (those should be placed in other chapters.) Include the expansion of the acronym when known.
Technically, the "acronyms" contained herein may be acronyms or initialisms and may be formed from initial or non-initial letters.
| Trial | Disease site | Title / Description | Reference |
|---|---|---|---|
| ACCORD | Action Clinique COordonnées en cancérologie Digestive (multiple trials) |
||
| ACCORD 11 | Pancreas | also: PRODIGE 4 | |
| ACORN | Breast | taxol +/- sorafenib | Gradishar WJ, San Anton 2009 |
| ALTTO | Breast | ||
| ARTIST | Gastric | Adjuvant Chemoradiation Therapy in Stomach Cancer | [1] |
| ASCENT2 | Prostate | castrate resistant | |
| ATLAS | Lung | second line maintenance | Miller VA, ASCO 2009 |
| AVADO | Breast | ? AVAstin and DOcetaxel | Miles D, ASCO 2008 |
| AVAGAST | Gastric | ||
| AZURE | Breast | zometa | |
| BEATRICE | Breast | A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer | http://clinicaltrials.gov/ct2/show/NCT00528567 |
| BENTLY | Lymphoma | ? BENdamustine T cell LYmphoma | Abstract |
| BETH | Breast | chemo + herceptin +/- Avastin | |
| BISMARK | Bone mets | zometa in bone mets | |
| BOLERO | Breast | Breast cancer trials of OraL EveROlimus | |
| BRIM3 | Melanoma | BRAF inhibitor Vemurafenib for MELANOMA | ASCO 2011 LBA4 |
| BRiTE | Colorectal | Bevacizumab Regimens: Investigation of Treatment Effects and Safety | [2] |
| CHEST | Lung | Chemotherapy for Early Stages Trial | PMID 22124104 |
| CINDERELLA | Glioma | carbon ion radiotherapy versus fractionated steretotactic radiotherapy in patients with recurrent or progressive gliomas | PMID 20925951 |
| CLASSIC | Gastric | Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer | ASCO 2011 - Bang - LBA 4002 |
| CLEOPATRA | Glioma | PMID 20819220 | |
| CLEOPATRA (another one) |
Breast | CLinical Evaluation Of Pertuzumab And TRAstuzumab | PMID 21147694 |
| COMICE | Breast | Multicentre randomised controlled trial examining the cost-effectiveness of contrast-enhanced high field magnetic resonance imaging in women with primary breast cancer scheduled for wide local excision (COMICE) | |
| CONFIRM | Breast | fulvestrant | Di Leo A, San Antonio 2009 |
| CORRECT | Colorectal | regorafenib | [3] |
| COSMIC | H&N / salivary | PMID 20937120 | |
| CRYSTAL | Colorectal | Cetuximab combined with iRinotecan in first line therapY for metaSTatic colorectAL cancer | [4] |
| DASISION | CML | dasatinib | |
| DEVA | Breast | Docetaxel Epirubicin Adjuvant | |
| EMBRACE | Breast | eribulin | Twelves C, ASCO 2010 |
| EVEREST | Colorectal | ? Erbitux ... | ASCO abstract |
| EVOLUTION | Myeloma | Kumar S, ASH 2009 | |
| EXPERT-C | Rectal | ? Eloxatin (oxaliplatin) Xeloda (capecitabine) Pre-operative Radiotherapy - Cetuximab | [5] |
| FACT | Breast | fulvestrant | Bergh 2009 |
| FIRST | Breast | fulvestrant | Ellis 2008 |
| First-SIGNAL | Lung | First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung | Abstract |
| GEPARDO | Breast | German Preoperative Adriamycin and Docetaxel | |
| GIDEON | HCC | Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with SorafeNib | ASCO 2011 - Marrero abs 4001 PMID 20642705 |
| HERA | Breast | ||
| IMPACT | Prostate | vaccine - Provenge | Kantoff P, 2010 abs. |
| INTACT | Lung | Iressa non–small cell lung cancer trial assessing combination treatment | |
| IPASS | Lung | Fukuoka M, ASCO 2009 abs | |
| LANDSCAPE | Breast Brain) |
brain mets her2. lapatinib. probably LApatiNib and CAPEcitabine | ASCO 2011 - 509 (T.Bachelor) |
| LOGiC | Gastric | Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer | [6] |
| MACRO | Colorectal | metastatic. maintenance bevacizumab | |
| MADeIT | Lung | Molecular Analysis Directed Individualized Therapy | Simon GR, Proc IASLC 2009 abst |
| MARCIE | Meningioma | PMID 21062428 | |
| MONET | Lung | MOtesanib NSCLC Efficacy and Tolerability Study | clinicaltrials.gov |
| MOSAIC | Colon | ||
| OCEANS | Ovarian | A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma | [7] |
| OPTIMIZE 2 | Breast Bone mets |
Zometa | |
| OPTIMOX | Colorectal | oxaliplatin | |
| OPUS | Colorectal | Cetuximab plus 5-FU/FA/oxaliplatin | PMID 21228335 |
| PASSPORT | Lung Brain mets |
Avastin | |
| PIVOT | Prostate | Prostate cancer Intervention Versus Observation Trial | |
| POET | Esophagus / Gastric | PreOperative chemotherapy or radiochemotherapy in Esophagogastric adenocarcinoma Trial | |
| PRIMA | Lymphoma | Primary RItuximab and MAintenance. Follicular lymphoma | |
| PRODIGE 4 | Pancreas | FOLFIRINOX. See ACCORD 11 | |
| QUASAR | Colorectal | eval Oncotype assay for Stage II CRC | Kerr D, ASCO 2009 |
| RIBBON-1 | Breast | capecitabine/Bev | Robert NJ, ASCO 2009 |
| RIBBON-2 | Breast | chemo/Bev 2nd line | Brufsky A, San Anton 2009 |
| SALUTE | Lung | A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer | PMID 21502556 |
| SATURN | Lung | second line maintenance | Cappuzzo F, ASCO 2009 |
| SELECT | Prostate | selenium and vitamin E cancer prevention trial | |
| SELECT (another one) |
RCC | high dose IL-2 | |
| SENTINA | Breast | sentinel node biopsy, neoadjuvant | |
| SHARP | HCC | sorafenib | Chang AI, Lancet Oncol 2009 |
| START | HCC | transcatheter arterial chemoembolization, sorafenib | |
| STEPP | skin toxicity evaluation protocol with panitumumab | Lacouture ME, JCO 2010, 1351 | |
| SUPREMO | Breast | Selective Use of Postoperative Radiotherapy AftEr MastectOmy | |
| TAILORx | Breast | oncotype dx | |
| TARGIT | Breast | targeted intraoperative RT | Vaidya, Lancet 2010 |
| TECHNO | Breast | Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups | |
| TITAN | Breast | AC-> vs AC->ixabepilone | |
| TOGA | Gastric | written as "ToGA" - trastuzumab gastric | Van Cutsem E, ASCO 2009 |
| TORAVA | RCC | temsirolimus + bevacizumab | |
| TORCH | Lung | A study of Tarceva OR CHemotherapy for the treatment of advanced NSCLC | clinicaltrials.gov |
| TRIBUTE (lung) | |||
| TROPIC | Prostate | metastatic, cabazitaxel | Sartor AO, 2010 abs |
| VELOUR | Colorectal | aflibercept | [8] |
| VERTICAL | Lymphoma | A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma (VERTICAL) | [9] [10] |
| ZEAL | Lung | ZACTIMA Efficacy with Alimta in Lung cancer | [11] |
| ZEPHYR | Lung | ZACTIMA Efficacy trial for NSCLC Patients with History of EGFR-TKI and chemo-resistance | Abstract [12] |
| ZEST | Lung | ZACTIMA Efficacy when Studied versus Tarceva | [13] |
| ZETA | Thyroid | medullary thryoid, vendetanib | |
| Z-FAST | Breast | zoledronic acid also: ZO-FAST and E-ZO-FAST |
Brufsky A, San Antonio 2009 |
| ZODIAC | Lung | ZACTIMA in cOmbination with Docetaxel In non-smAll cell lung Cancer | [14] |
| ZORO | Breast | goserelin / zoladex. GBG 37 ZORO Study | PMID 21537042 |